ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities
View original at finance.yahoo.com“The Company ended the quarter with an estimated $380.9 million in cash, cash equivalents and marketable securities as of March 31, 2026.”
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Following strong growth in 2025, ImmunityBio is focused on scaling in the U.S. and expanding across an increasing number of global markets
60% confidenceANKTIVA's continued momentum reflects growing physician adoption and disciplined commercial execution
60% confidenceFull enrollment of the pivotal BCG-naïve CIS trial with IDMC confirmation of adequate statistical power further strengthen the expanding body of clinical evidence supporting ANKTIVA in the NMIBC bladder cancer setting
60% confidenceSupplemental BLA submission for BCG-naïve indication is on track for 2026
60% confidenceThe sustained momentum of ANKTIVA reflects its growing commercial adoption in the BCG-unresponsive NMIBC CIS setting and feedback from treating urologists has been consistently positive
60% confidence